Search for Joe Jimenez and
    1. July 19, 2016

      Novartis braced for US price shake-up after presidential election

      Novartis, the Swiss pharmaceuticals group, has said it is preparing for a tougher US price environment after the...

    2. June 1, 2016

      Novartis boss says China will continue to outstrip Europe and US

      Pharmaceutical sales growth in China will continue to outstrip Europe and the US despite the economic slowdown on the...

    1. Fast FT

      April 21, 2016

      Novartis profits drop in Q1

      Falling sales and slow sales of a vaunted new heart drug – it was much the same story for Novartis in the first months...

    2. April 18, 2016

      Clouds gather over Novartis as it battles series of setbacks

      Joe Jimenez is facing a battle to restore investor confidence in Novartis after a series of setbacks which have sent...

    3. January 27, 2016

      Novartis revamps Alcon eyecare division

      Novartis has set a deadline for its struggling eyecare business to return to growth by the end of this year or risk...

    4. October 27, 2015

      Novartis to pay $390m to settle kickback claims

      Novartis will pay $390m to settle US allegations that it used kickbacks to specialist pharmacies to push sales of some...

    5. September 15, 2015

      Philips to spin off lighting arm and step up medical tech drive

      From the earliest lightbulbs and transistor radios to the first flatscreen televisions, Philips was Europe’s...

    6. July 22, 2015

      Alzheimer’s breakthrough hopes add to promise of pharma revival

      Hopes of a breakthrough against Alzheimer’s disease have been boosted by encouraging clinical trial data from Eli Lilly...

    7. July 21, 2015

      Novartis chief looks to blockbuster drugs to counter profits drop

      Novartis’s chief executive has urged investors to look beyond the Swiss group’s disappointing second-quarter results...

    8. June 7, 2015

      Novartis chief backs shake-up in drug pricing

      Pharmaceutical companies must move towards new pricing models based on outcomes for patients if Europe’s cash-strapped...

    9. April 23, 2015

      Novartis starts to reap rewards of revamp

      Novartis announced better than expected first-quarter profits on Thursday as it began to show the benefits of a...

    10. March 22, 2015

      Apple and Google stake a claim on big pharma’s turf

      Within 24 hours of Apple launching its platform for health research this month, tens of thousands of iPhone users had...

    11. March 8, 2015

      Novartis leads way for big pharma cost-cuts

      Novartis is showing the way for big pharmaceutical groups to become more productive, according to its chief executive,...

    12. March 2, 2015

      GSK-Novartis deal ‘a model’ for industry

      A $2bn disposal by Johnson & Johnson and the completion of a $20bn asset swap between GlaxoSmithKline and Novartis on...

    13. January 27, 2015

      Novartis vows cost cuts after Swiss franc surge

      Novartis has leapt to the defence of the Swiss National Bank for removing the cap on the Swiss franc against the euro...

    14. July 17, 2014

      Novartis maintains forecasts despite weak quarter

      Novartis confirmed its full-year profit and revenue forecasts, despite weaker than expected second-quarter results and...

    15. April 24, 2014

      Novartis profits boosted by sales in emerging markets

      Novartis posted a 23 per cent jump in net profits in the first quarter, thanks to the sale of one of its diagnostics...

    16. April 22, 2014

      GSK chief quick to distance Novartis deal from megamerger mania

      Another day, another big pharma deal. Novartis and GlaxoSmithKline became the latest companies to join the industry’s...

    17. April 22, 2014

      Novartis chief Joe Jimenez makes biggest move at group

      The multibillion-dollar reshaping of Novartis announced on Tuesday is easily the most significant move that Joe...

    18. April 22, 2014

      Novartis buys GSK business for up to $16bn in restructuring

      Novartis and GlaxoSmithKline have agreed to swap a series of assets in a multibillion-dollar deal that will reshape two...

    19. April 2, 2014

      Big pharma’s rise in China not held back by scandals

      When Chinese authorities accused GlaxoSmithKline last summer of being the “godfather” at the centre of a network of...

    20. March 10, 2014

      Novartis restructure marks break from expansion

      It is four years since Joe Jimenez took over as chief executive of Novartis. But, in some ways, it feels as if he is...

    21. February 16, 2014

      Novartis puts pressure on India over patent abuse

      Novartis has urged US and European governments to “apply pressure” on India to respect intellectual property and warned...

    22. February 13, 2014

      Recent votes call into question Swiss hospitality to business

      Few countries have been more hospitable to business than Switzerland. Its stable laws and favourable tax regime have...

    23. January 29, 2014

      Novartis considers future of $14bn Roche stake

      Novartis’s $14bn stake in its local rival Roche is one of the assets it is scrutinising as part of a broader review of...

    24. December 8, 2013

      Change without sour grapes

      When Jörg Reinhardt rejoined Novartis in August to take up his new role as chairman of the Swiss pharmaceutical group,...

    25. November 11, 2013

      Novartis agrees $1.7bn sale of blood diagnostics unit to Grifols

      Novartis has agreed to sell its blood diagnostics unit to the Spanish healthcare group Grifols for $1.7bn, in the first...

    26. June 17, 2013

      Novartis pioneers health project in rural China

      China may be one of the world’s largest markets for companies from Rolls-Royce to Rolex, but beneath that veneer of...

    27. February 24, 2013

      Novartis’ U-turn marks a crossroads

      Daniel Vasella may have struggled at first to speak English when he was sent to the US on his first pharmaceutical...

    28. January 23, 2013

      Vasella to step down as Novartis chairman

      Shares jumped sharply at Novartis on anticipation of a shift in strategy at the Swiss healthcare group, following the...

    29. July 19, 2012

      Novartis offsets effects of patent expiry

      Novartis reported second-quarter net income unchanged at $2.7bn and maintained existing full-year 2012 guidance,...

    30. April 26, 2012

      Simon Lowth, interim CEO AstraZeneca

      Simon Lowth’s appointment as interim chief executive of AstraZeneca puts him in a strong position as the long-term...

    31. February 5, 2012

      Pharma seeks to ease pain of euro crisis

      With Greece and Spain struggling to repay billions of euros in outstanding debts to the healthcare sector as the...

    32. January 25, 2012

      Novartis upbeat despite end of Diovan patent

      Novartis forecast it would maintain sales and suffer only potentially slightly lower operating profits this year,...

    33. October 25, 2011

      Novartis to cut 10% of Swiss workforce

      Novartis will cut its core Swiss workforce by almost 10 per cent, in the latest attempt by a top pharmaceuticals group...

    34. June 27, 2011

      China: Pharma heads east for profit

      After 30 years of economic reform in China, the growing middle class is discovering there is more to life than working...

    35. April 19, 2011

      Novartis profit hit by costs of Alcon buy-out

      Novartis boosted sales in the first quarter, but the Swiss pharmaceuticals group’s net profits fell because of higher...

    36. March 16, 2011

      Novartis plans to close drugs factory

      Novartis has dealt a fresh blow to the UK’s historical strength in the pharmaceutical sector with plans to reduce...

    37. January 27, 2011

      Novartis confident despite market pressures

      Novartis remains optimistic about the current year, in spite of intensifying pricing pressure in many markets as...

    38. December 15, 2010

      Novartis climbs down to clinch Alcon

      Novartis has backed down in its battle with the independent directors of Alcon by agreeing to pay an extra $1bn to buy...

    Search for Joe Jimenez and

    RELATED VIDEOS

    Videos from FT.com that closely match this topic

    1. Novartis CEO on new growth opportunities...
      July 26, 2015

      Novartis CEO on new growth opportunities